SpotDraft’s software includes AI-assisted redlining tools, which is the process of editing a contract where two or more ...

Google also released an experimental version of Gemini 2.0 Pro, the company’s flagship model with the best performance for ...

Keep your eye on the ball” is a motto for many athletes—and for astronomers trying to find Earth-threatening space rocks ...

Maxcyte's technology helped Vertex Pharmaceuticals Inc. (NASDAQ ... usually at a 45-degree or higher angle. The flagpole completes when the stock forms its peak. The flag is formed on the parallel ...

ByteDance’s OmniHuman-1 generates lifelike human videos from a single image and audio. Discover its key features and compare it with Sora and Veo 2.

South Australian solar solutions company Venergy Solar has completed a multi-rooftop solar installation in eight weeks, in ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...